Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in ...

Market Implications: The ongoing study could influence the stock performance of Regeneron Pharmaceuticals and Sanofi, as successful results may enhance investor confidence and market valuation.

TARRYTOWN, N.Y. and PARIS, May 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented late-breaking data from the NOTUS Phase 3 trial evaluating the ...

TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that a Dupixent ® (dupilumab) pivotal trial (ADEPT) in bullous ...

To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.

Sept 11 (Reuters) - Regeneron Pharmaceuticals IncUS Supreme Court upholds law banning TikTok Legal · January 17, 2025 · 7:13 AM PST · 9 min ago The U.S. Supreme Court refused to rescue TikTok ...

--Regeneron Pharmaceuticals, Inc. and Sanofi today announced the New England Journal of Medicine has published results from a positive Phase 3 trial for Dupixent ® in children aged 1 to 11 years ...

Treatment with dupilumab also had a significant improvement on lung function (change in pre-bronchodilator FEV 1 from baseline to week 12: 139mL vs 57mL for placebo; P =.0001) that was sustained ...

To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.

At 24 weeks, histologic remission occurred in 60% of patients in Part A of the trial and 59% in Part B who received a weekly 300-mg dose of dupilumab compared with 5% and 6% taking placebo.

These results add to previous evidence from the BOREAS trial, which supports dupilumab (Dupixent; Regeneron, Sanofi) use in this patient population, according to the press release from Sanofi.